

1 Selection for infectivity profiles in slow and fast 2 epidemics, and the rise of SARS-CoV-2 variants

3
4 François Blanquart¹, Nathanaël Hozé², Benjamin J. Cowling^{3,4}, Florence Débarre⁵, Simon
5 Cauchemez²

6 1. Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS,
7 INSERM, PSL Research University, Paris, France

8 2. Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de
9 Paris, UMR2000, CNRS, Paris, France

10 3. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School
11 of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
12 Pokfulam, Hong Kong Special Administrative Region, China

13 4. Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park,
14 New Territories, Hong Kong Special Administrative Region, China

15 5. Institute of Ecology and Environmental Sciences of Paris (iEES-Paris, UMR 7618),
16 CNRS, Sorbonne Université, UPEC, IRD, INRAE, 75252 Paris, France

17 Abstract

18 Evaluating the characteristics of emerging SARS-CoV-2 variants of concern is essential to
19 inform pandemic risk assessment. A variant may grow faster if it produces a larger number of
20 secondary infections (transmissibility advantage) or if the timing of secondary infections
21 (generation time) is better. So far, assessments have largely focused on deriving the
22 transmissibility advantage assuming the generation time was unchanged. Yet, knowledge of
23 both is needed to anticipate impact. Here we develop an analytical framework to investigate
24 the contribution of both the transmissibility advantage and generation time to the growth
25 advantage of a variant. We find that the growth advantage depends on the epidemiological
26 context (level of epidemic control). More specifically, variants conferring earlier transmission
27 are more strongly favoured when the historical strains have fast epidemic growth, while
28 variants conferring later transmission are more strongly favoured when historical strains have
29 slow or negative growth. We develop these conceptual insights into a statistical framework to
30 infer both the transmissibility advantage and generation time of a variant. On simulated data,
31 our framework correctly estimates both parameters when it covers time periods characterized
32 by different epidemiological contexts. Applied to data for the Alpha and Delta variants in
33 England and in Europe, we find that Alpha confers a +54% [95% CI, 45-63%] transmissibility
34 advantage compared to previous strains, and Delta +140% [98-182%] compared to Alpha, and
35 mean generation times are similar to historical strains for both variants. This work helps
36 interpret variant frequency and will strengthen risk assessment for future variants of concern.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 Introduction

38 Human pathogens rapidly adapt to their hosts. During the short evolutionary history of SARS-
39 CoV-2 with humans, since the host shift in late 2019, several selected mutations and
40 combinations of mutations (variants) have emerged: for example, the D614G mutation in
41 Spring 2020 (1), the variant Alpha in Fall 2020 (B.1.1.7), and Delta in Spring 2020 (B.1.617.2).
42 Variant Alpha, first detected in England in September 2020, rapidly rose in frequency in
43 October 2020 in England and spread to multiple countries, causing important rebounds of the
44 epidemic (2–6). Since then, the Delta variant has become dominant in many parts of the world,
45 leading to new surges in infections and hospitalisations.

46 Each time a variant of concern emerges, it is essential to determine whether it has acquired a
47 competitive advantage compared to circulating SARS-CoV-2 strains, in order to anticipate the
48 potential effects on the epidemic trajectory and hospital admissions. The advantage can be
49 caused by an increased capacity to transmit or to escape the immune response acquired by
50 previous infection or vaccination. The *transmissibility advantage* of an emerging variant has
51 been defined as the relative increase in the effective reproduction number R (average number
52 of secondary cases). It has often been estimated by analysing the rise in the variant's frequency,
53 under the assumption that all strains shared the same generation time (GT) distribution (i.e.
54 delay between infection in the primary case and the people they infect). However, this has
55 sometimes led to unstable estimates of the transmissibility advantage. For example, in the
56 United Kingdom, the transmissibility advantage of the Alpha variant was estimated to decline
57 from +89% to +54% from December to mid-January. Estimates of transmissibility advantage
58 of Alpha and Delta across countries also exhibit substantial variability (7). The reasons why
59 estimates of the transmissibility advantage would vary with the epidemiological context remain
60 obscure. The instability this generates is problematic for planning since it affects medium and
61 long-term evaluations of the epidemic trajectory. It also suggests that methods currently used
62 to ascertain the risks posed by emerging variants may miss important drivers of emergence.

63 The evolutionary fate of the variant is ultimately determined by its exponential growth rate
64 relative to that of the circulating strains. When evaluating the growth advantage of a variant,
65 the focus has so far largely been on estimating differences in R . However, the growth rate of
66 an emerging variant depends not only on the effective reproduction number but also on the
67 generation time (GT) distribution. Natural selection is therefore expected to act on the full
68 infectivity profile, which combines both R and GT. Here we develop a mathematical model to

69 investigate how the growth advantage may vary with the epidemiological context when
70 variants have different generation times. We use the relationship between infectivity profile
71 and growth rate to explore conceptually how infectivity profiles are selected for. We find that
72 the growth advantage of a variant generally depends on the epidemiological context, more
73 precisely on whether transmission is low (declining or slow epidemic) or high (fast epidemic).
74 We call transmission the rate of infectious contacts in the community, which depends on the
75 epidemiological context, for example social distancing, mask-wearing, population immunity,
76 seasonal effects, etc. We use the time-varying reproduction number of the historical strain
77 (taken as a reference), denoted $R_H(t)$, as a proxy for transmission. Our conceptual exploration
78 suggests that it is possible to infer changes in infectivity profile associated with an emerging
79 variant, and not only its growth rate, in settings where transmission changes over time. We thus
80 develop an inference framework to estimate changes in infectivity profile associated with a
81 variant and more precisely characterize the transmissibility advantage of the variant and its
82 dependency to the epidemiological context. We apply our approach to data on Alpha and Delta
83 variants frequency over time in England in Fall 2020 and Spring 2021.

84 Results

85 General principle

86 We consider a situation where a variant, or a set of strains with similar properties, have been
87 circulating for some time (historical strains H) and is challenged by an emerging variant E .
88 When investigating the rise of variant E relative to historical strains H , we typically only
89 observe the exponential growth rates of H and E strains, which translates into a growth
90 advantage (or disadvantage). More precisely, if the historical strains grow with exponential rate
91 r_H and the emerging variant grows with rate r_E , the logit of the frequency of the emerging
92 variant will grow linearly with slope $r_E - r_H$. This slope is called the growth advantage or
93 selection coefficient. The selection coefficient of the emerging variant relative to historical
94 strains is obtained by a linear regression of the logit frequency of the variant over time. It is
95 then typically assumed that both variant and historical strains share the same distribution of
96 generation time. The effective reproduction number of the emerging variant relative to
97 historical strains, called the transmissibility advantage ($R_E/R_H - 1$), can thus be deduced.
98 Yet natural selection acts on the full infectivity profile of a strain, not only on the effective
99 reproduction number. The infectivity profile is a function $\beta(\tau) = R w(\tau)$ of the time since

100 infection τ , where R is the effective reproduction number, while $w(\tau)$ characterizes the
101 distribution of generation time and satisfies $\int_{\tau=0}^{\infty} w(\tau)d\tau = 1$.

102 Selection for infectivity profiles in slow and fast epidemics

103 We first examine how the selection coefficient $r_E - r_H$ varies with transmission for various
104 infectivity profiles of the variant compared to historical strains (Figure 1). To do so, we use a
105 formula relating the growth rate to the effective reproduction number and the distribution of
106 the generation time (Methods). This formula assumes that each variant grows or declines
107 exponentially and that the distribution of the time since infection is at any time at its equilibrium
108 value: an exponential distribution with rate equal to the exponential growth rate (8). This
109 equilibrium distribution naturally follows from the assumption of exponential growth, which
110 implies that individuals infected $t + \Delta t$ days ago are $e^{r \Delta t}$ more numerous than individuals
111 infected t days ago, with r is the exponential growth rate.


112 Several scenarios for the emerging variant are considered. We first consider variants with the
113 same effective reproduction number as historical strains, which can be selected for if secondary
114 infections occur at different timings (Figure 1 A, C). A variant with a shorter mean generation
115 time is selected in a growing epidemic because it produces the same number of secondary
116 infections in a shorter time, while the same variant is counter-selected in a declining epidemic
117 (Figure 1C). The opposite holds for variants with a longer mean generation time. A variant
118 with larger standard deviation (sd) in generation time is always selected for because it enjoys
119 both an excess of early secondary infections and late secondary infections compared to
120 historical strains. The opposite holds for a variant with smaller sd in generation time. Generally,
121 in a growing epidemic, more individuals have been infected recently and there is a greater
122 advantage to early transmission, while in a declining epidemic, more individuals have late time
123 since infection and therefore strains that transmit at later times have a greater advantage. Again,
124 this is a direct demographic consequence of growth or decline of the epidemic. Selected
125 variants could thus enjoy a more favourable timing of secondary infections, not a
126 transmissibility advantage (9).

127 Additionally, an advantage in the timing of secondary infections can of course be combined
128 with a transmissibility advantage. We therefore consider hypothetical emerging variants with
129 a range of generation time distributions and a +10% transmissibility advantage (Figure 1B, D).
130 These variants generally have a stronger growth advantage, but the variation in selection

131 coefficient with transmission is similar to that of the analogous variants without the
132 transmissibility advantage (Figure 1C, D).

133 Notably, in both cases there is a level of transmission (R_H) at which all variants perform
134 similarly regardless of their distribution of generation time. This level of transmission is
135 precisely where the size of the variant epidemic is constant in time (variant growth rate is 0).
136 For example, this level of transmission is $R_H = 1$ for a variant not affecting transmissibility
137 (Figure 1C). For a 10% transmissibility advantage, this level is $R_H = 1/1.1$ (Figure 1D).
138 Generally, for a variant conferring a transmissibility advantage s_1 , the level of transmission is
139 $R_H = 1/(1 + s_1)$. At this level of transmission, the distribution of time since infection is
140 uniform—all ages of infection are equally represented—and therefore the infectivity profile
141 does not matter for selection on the variant.


142 While these results assume that the time since infection is fixed at its equilibrium distribution,
143 it is not necessarily the case in a realistic scenario where transmission changes over time. We
144 applied these analytical results to simulations where the time since infection structure emerges
145 from the model dynamics. The epidemiological dynamics are simulated with discrete-time
146 renewal equations including time-varying transmission, the build-up of population immunity
147 (assumed to be identical for historical strains and emerging variant), and detection and isolation
148 of cases (Methods). In the context of progressive control of an epidemic, variants with the same
149 reproduction number but distinct generation time distributions can exhibit a variety of
150 epidemiological and frequency dynamics (Figure 2A, C). The epidemiological dynamics, that
151 is the daily number of variant cases, are also strongly affected by the generation time
152 distribution of the variant (Figure 2A). Frequency trajectories can be non-monotonous: a
153 variant with shorter mean generation time could be selected, increase in frequency, but then
154 decline in frequency as the epidemic is controlled (Figure 2C). Several variants all sharing the
155 same 10% transmissibility advantage exhibit a range of frequency trajectories in the
156 simulations: the trajectories of one of them resemble that of a variant with a +30% advantage
157 and same generation time distribution as historical strains (Figure 2D, light blue line compared
158 to +30% curve), while others stagnate at low frequency (Figure 2D, blue and green lines).



159

160 **Figure 1:** Variation of the selection coefficient as a function of transmission, for several infectivity profiles of
 161 emerging variants. Panels A, B show several variant infectivity profiles with the same effective reproduction
 162 number as historical strains (A) or an effective reproduction number increased by +10% (B). For variants with
 163 shorter or longer mean generation time, the relative mean generation time is -15% or +15% compared to historical
 164 strains. For variants with shorter or longer sd in generation time, the relative sd in generation time is -40% or
 165 +40% compared to historical strains. The Panels C, D show for these variants, the selection coefficient as a
 166 function of the proxy for transmission (effective reproduction number of the historical strains). The gray lines
 167 show the selection coefficient if the variant had the same infectivity profile as historical strains, only increased
 168 uniformly by a constant as commonly assumed.

169



170

171 **Figure 2:** Epidemiological and evolutionary trajectories of several types of emerging variants competing with
 172 historical strains. Panels A, B show epidemiological dynamics (daily cases number of historical strains in black,
 173 of variants in colours). Historical strains display several slightly different curves when competing with each of
 174 the variants because of the weak competition brought about by the build-up of population immunity. Panels C, D,
 175 show evolutionary trajectories, with daily variant frequency as coloured lines. The light gray curves show the
 176 frequency dynamics of variants with a +10% to +50% transmissibility advantage, with the same generation time
 177 as historical strains. The inset shows the transmission through time in these simulations, given by the basic
 178 reproduction number of historical strains (see details of simulation model in Methods).

179 Inference of the infectivity profiles of variants


180 The variety of variant trajectories shown on Figure 2 suggests that it may be possible to infer
 181 the changes in infectivity profiles of variants by analysing their growth advantage as a function
 182 of transmission when we have accumulated sufficient data documenting growth rates in
 183 different epidemiological situations. We first tested this idea on simulated data, in scenarios of
 184 emergence and progressive control of the variant.

185 Our inference framework is based on the relationship between growth rates of historical strains
186 (r_H) and of the emerging variant (r_E). Our aim is to infer three parameters s_1 , s_2 , s_3 ,
187 characterizing respectively the transmissibility advantage, the mean generation time and the sd
188 of generation time of the emerging strain relative to that of historical strains. The relationship
189 can be used to infer properties of the variant infectivity profile, but not with a classical linear
190 regression because both r_H and r_E are measured with errors with a complex covariance
191 structure. Furthermore, large errors can blur the subtle distinction between different profiles
192 (Supplementary Figure 1). The error variance is inversely related to the number of cases and
193 the size of the sample used to assay variant frequency (“sample size”). When the total number
194 of cases and the sample size are both large, the joint distribution of the time series of estimated
195 \hat{r}_H and \hat{r}_E is approximately multivariate normal (Methods). The mean vector of the multivariate
196 normal depends on the parameters $R_H(t)$ (the time series of effective reproduction number), of
197 the mean and sd of the historical strains’ generation time (fixed to 6.5 and 4 days), and of the
198 parameters of interest s_1 , s_2 , s_3 . The variance-covariance structure of the multivariate normal
199 distribution is fixed and depends on the daily total number of cases and the sample size. It is
200 also possible to derive the multivariate normal distribution of \hat{r}_H and \hat{r}_E across different
201 independent regions instead of over time (Methods).

202 With this statistical framework at hand, we conducted a simulation study to infer jointly the
203 transmissibility advantage of the variants and their relative mean generation time (Figure 3). In
204 these simulations, we systematically varied the infectivity profile of the emerging strain:
205 transmissibility advantage (s_1) from +0 to +50% and relative mean generation time (s_2) from
206 -40% to +40%. We assumed the emerging strain had the same sd of generation time as
207 historical strains ($s_3 = 0$). We jointly inferred the two parameters s_1 and s_2 for different
208 sample sizes (sample size, $N = 1000, 3000, 10000$ per day) and for different scenarios of
209 variability in epidemiological context, from a strong to a weak decline. In the explicit
210 simulations, the parameter that we tune is the *basic* reproductive number $R_{0,H}(t)$ assumed to
211 decline from 1.5 to 0.5, 1.3 to 0.7 and 1.1 to 0.9 over 80 days in the three scenarios, and the
212 inferred parameters represent the *effective* reproductive number after accounting for population
213 immunity and case detection and isolation (Supplementary Figure 2).

214 The transmissibility advantage was almost always precisely inferred even with small sample
215 size and small variability in effective reproduction number (Figure 3, left panels). In contrast,
216 the relative mean generation time was well inferred only for a large sample size and large
217 variability in effective reproduction number (Figure 3, right panel). This was because the large

218 error on r_E and r_H due to the limited sample size, in conjunction with the small variability in
 219 $R_{0,H}(t)$ makes precise inference of the relationship between r_E and r_H difficult. For such small
 220 sample sizes, grouping data by week (instead of by days, for the same duration) improves
 221 inference (Figure 3, green points).



222

223 **Figure 3:** Inference of the transmissibility advantage and relative mean generation time in the simulation study.
 224 The plots show the correlation between inferred and true quantities. The three colours show different sample sizes
 225 used to infer variant frequency: 1000 daily, 10000 daily, and 1000 daily grouped by week (7,000 weekly). The
 226 left panels show the transmissibility advantage, the right panels the mean generation time (mgt). Top, middle and
 227 bottom panels show inference for large, medium and small variability in $R_{0,H}(t)$. The simulations are initialized
 228 with $I_H(0,0) = 4000$ and $I_E(0,0) = 80$. For the inference of the transmissibility advantage we used a variant
 229 relative mean generation time of $s_2 = +0\%$ (also inferred by the model), while for the inference of relative mean

230 generation time we used a variant transmissibility advantage of $s_1 = +30\%$ or $s_1 = +45\%$ (for relative mean
231 generation time $s_2 = +20\%$ and $s_2 = +40\%$). For each parameter combination, 10 replicate simulations were
232 drawn with the same parameters, hence the same deterministic epidemiological dynamics, but with different
233 random error on data (Poisson error on cases number and binomial error on frequencies).

234 Application to the variants Alpha and Delta in England

235 We used this framework to infer the transmissibility advantage and mean generation time of
236 Alpha (B.1.1.7) in England. We used public data from Public Health England on weekly cases
237 numbers and frequency of the Alpha variant (dataset 1). In England, the frequency of the Alpha
238 variant could be quickly inferred because some of the PCR tests for SARS-CoV-2 detection
239 presented a “S gene target failure” (SGTF) caused by the spike 69/70 deletion characteristic of
240 Alpha (10). The variant Alpha swept through from 0% to almost 100% frequency over 25
241 weeks; data were of very good quality for the whole period (Figure 4). Using our framework,
242 we found that Alpha had a transmissibility advantage equal to $s_1 = 54\%$ [45, 63%], and the
243 same mean generation time as previous strains, $s_2 = 0.058$ [−0.095, 0.21] (Figure 5).

244 We next evaluated the growth of Delta (B.1.617.2) in England. As Delta does not have the
245 spike 69/70 deletion, the growth of Delta and eventual replacement of Alpha in April and May
246 2021 was evidenced by the decline of SGTF (11) (dataset 2). However, we found that with this
247 temporal data, we could not reliably disentangle the transmissibility advantage from the mean
248 generation time. The confidence intervals were very wide, with an estimated transmissibility
249 advantage equal to $s_1 = 229\%$ [7, 451%] and a mean generation time estimated at $s_2 =$
250 1 [−0.31, 2.3]. This was linked to the small temporal variations in epidemic conditions in this
251 short period of time compared to the previous period when we investigated Alpha
252 (Supplementary Figure 3).


253 In an attempt to gain more power to disentangle the transmissibility advantage from the mean
254 generation time for the Delta variant, we used *spatial* variation in growth rates across European
255 countries. We used data from the European Surveillance System (TESSy) on the growth rate
256 of “historical” strains circulating at the time when Delta emerged (mainly Alpha variant), and
257 the emerging Delta variant across 11 European countries with sufficient genomic data (Austria,
258 Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Sweden:
259 dataset 3). With these data, we inferred a transmissibility advantage equal to $s_1 =$
260 140% [98, 182%] compared to Alpha, and a mean generation time similar to the Alpha variant
261 at $s_2 = 0.033$ [−0.18, 0.25].

262 In conclusion, we found that the Alpha variant had a transmissibility advantage of +54%
 263 compared to historical strains, and the Delta variant had a further transmissibility advantage of
 264 +140% relative to Alpha, assuming a mean generation time of 6.5 days. There was no evidence
 265 of an altered mean generation time for these two variants. Intuitive patterns in the inferred
 266 relationship testify from the fact that Alpha and Delta have (Figure 5): the relation between
 267 growth rates r_E and r_H runs almost parallel to the bisector, indicating that the selection
 268 coefficient does not change much with epidemiological conditions. The analytical relationship
 269 between r_E and r_H would imply on the contrary a steeper slope for a variant shortening the
 270 mean generation time, and a flatter slope for a variant prolonging the mean generation time
 271 (Methods, Figure 5A, Supplementary Figure 1).

272

273


274



275

276 **Figure 4:** Data used for inference. Top panels, dynamics of the Alpha variant frequency in England (left) and of
 277 the Delta variant frequency in England (right), estimated through SGTF. These frequencies are shown together
 278 with the dynamics of weekly cases numbers, over weeks 35 (week starting 08/09/2020) to 60 (week starting
 279 02/03/2021) for Alpha, and weeks 63 (starting 23/03/2021) to 75 (starting 15/06/2021) for Delta. Bottom panel,

280 the dynamics of the Delta variant frequency in 11 chosen European countries. For each country we used the
 281 growth rate of historical strains and emerging Delta variant when the frequency passes 50%, highlighted with
 282 larger points and thicker line on the figure.
 283



284
 285 **Figure 5:** A, Geometric intuition for how the (r_H, r_E) relationship depends on the mean generation time for
 286 hypothetical variants with transmissibility advantage $s_1 = 0.1$ and relative mean generation time of $s_2 = -0.15$
 287 and $s_2 = +0.15$ (as in Fig. 1, 2). B, the correlation between estimated growth rates of historical strains and variant
 288 in England. For Alpha (dataset 1) this is a temporal correlation in England over weeks starting 08/09/2020 to
 289 16/03/2021. For Delta (dataset 3) this is a *spatial* correlation across European countries. The curves with
 290 confidence intervals are the model fits for each variant and show that the selection coefficient (the vertical distance
 291 to the bisector) is roughly constant across epidemiological conditions, indicative that the mean generation time is

292 not altered in these variants. C , the inferred infectivity profile of each variant with confidence intervals, together
293 with the infectivity profile of historical strains circulating before the rise of the Alpha variant (black curve).

294

295

296 Discussion

297 We investigated how emerging variants with distinct infectivity profiles may be selected. Our
298 main finding is that levels of transmission reflected in the reproduction number $R(t)$, which
299 depend on human behaviour and interventions, change selection on different types of variants.
300 In a context of high transmission and high growth rate (“fast” epidemic), most infections will
301 be recent and it is more advantageous to transmit early. Conversely, in a context of low
302 transmission (“slow” or declining epidemic), infections will be older and it is more
303 advantageous to transmit late. The selection coefficient on variants may thus increase or
304 decrease with transmission, and it can even be a non-monotonous function of transmission. A
305 second important finding is the variation of the selection coefficient with transmission provides
306 insight on the infectivity profile. We used this understanding to infer variant infectivity profiles
307 from the variation in growth rates in contexts of changing transmission.

308 We found that Alpha variants enjoy a transmissibility advantage of +54% [45, 63] relative to
309 historical strains, and Delta variants a +140% [98, 182] additional advantage relative to Alpha.
310 Both variants have a mean generation time similar to that of historical strains (here assumed to
311 be 6.5 days). This complements previous findings: the possibility of a shorter generation time
312 was investigated to explain the growth advantage of Alpha, but previous studies found it was
313 difficult to distinguish a variant with larger transmissibility from one with a shorter generation
314 time (2,3). Some (but not all) studies of within-host viral load dynamics suggested that
315 individuals infected by variant Alpha could shed virus for a longer time, which may result in a
316 longer generation time (12–14). Conflicting results exist for Delta. A cluster of Delta variant
317 infections in China suggested a smaller mean generation time (2.9 days) and more pre-
318 symptomatic transmission for Delta than early SARS-CoV-2 strains, but without good control
319 (15); more controlled studies found on the contrary a similar generation time (16,17). If the
320 distribution of generation time is similar in Delta as we infer, the observed growth rates imply
321 it is +140% more transmissible than Alpha, in line with the +70 to +200% estimated elsewhere
322 (18,19). If the generation time of Delta had instead been inferred 1 or 2 days shorter than the
323 baseline (6.5 days), the observed growth rate would imply the estimated transmissibility

324 advantage drops to +106% or +77%. The large transmissibility advantage of Delta with similar
325 mean generation time makes it more difficult to control with interventions reducing
326 transmission (such as social distancing) than if it had a smaller transmissibility advantage
327 associated with a shorter mean generation time.

328 Our conceptual results may be useful to interpret the dynamics of variant frequency dynamics.
329 Frequency dynamics are determined by the selection coefficient, which is the difference in
330 growth rates between the variant and historical strains. Several papers have reported a varying
331 selection coefficient across time (20) or across countries (7). One possible explanation for this
332 variability is that the selection coefficient changes with transmission because of differences in
333 generation time distributions, which may explain non-monotonous frequency trajectories
334 (Figure 2C).

335 Evolution influences epidemiological dynamics: at a given level of transmission, stronger
336 selection on a variant also implies a larger incidence of the variant and therefore a larger burden
337 on healthcare systems (Figure 2A). However, we emphasize that measures to reduce
338 transmission, although possibly increasing the *selection coefficient*, always result in reduced
339 variant *absolute growth rate* and better control of the variant. Indeed, it remains true that a
340 variant epidemic growth rate is an increasing function of transmission, and a variant is growing
341 if and only if $R_E > 1$ (Equation 3).

342 A limitation of our framework is that we only consider the impact of changing transmission on
343 selection for variants. We do not consider the impact of interventions shortening the
344 distribution of generation time such as isolation of positive cases and contact tracing, which
345 also potentially change over time (21). These interventions would alter the selection coefficient
346 differently, in particular would favour earlier transmission (shorter mean generation time). We
347 do not consider either the impact of other changes in the environment. For example, the positive
348 selection on vaccine escape variants may increase over time in the context of rapid vaccination
349 of the population. Analogously, different levels of vaccination across countries could also
350 affect the spatial analysis of spread of a vaccine escape variant. Lastly, we consider only one
351 emerging variant. Our inference framework could readily be extended without additional
352 technical complications to the frequency dynamics of several variants. In spite of these
353 limitations, our simple framework makes minimal assumptions (exponential growth rate and
354 stable age-of-infection structure) that proved robust when tested against a simulation model
355 including more complicated features (build-up of immunity, isolation of positive cases, explicit
356 epidemiological dynamics in the context of changing transmission).

357 In conclusion, we developed a conceptual framework to study selection on variants modifying
358 the transmission of an infectious pathogen. We decoupled selection on transmissibility (number
359 of secondary infections) and selection on the distribution of generation time (timing of
360 secondary infections). While selection on number of secondary infections is stronger with
361 increased transmission (e.g., contact rates) in the community, selection on the generation time
362 varies with levels of transmission in the community. This can lead to non-monotonous variant
363 frequency trajectories. The ensuing variation in the selection coefficient in contexts of changing
364 transmission can be used to infer not only the transmissibility advantage of variants, but also
365 the change in mean generation time. This inference method could be used in conjunction with
366 other type of data, for example data on variant viral load trajectories (13,22), or comparison of
367 secondary attack rates of variant vs. historical strains informing on the transmissibility
368 advantage (23). We find that the patterns of growth of the Alpha and Delta variants in England
369 and in Europe are compatible with mean generation times similar to historical strains. This
370 work will help understand variant dynamics at a time when several variants of concern are
371 circulating and new ones may evolve, and genomic and PCR-based surveillance programs
372 allow fine monitoring of their dynamics.

373

374 Methods

375 The model

376 Relationship between growth rate and effective reproduction number

377 We describe the exponential growth of an epidemic within a simple framework. We assume
378 that transmission changes over time because of varying social distancing measures. We assume
379 that changes are sufficiently slow compared to the mean generation time that the distribution
380 of time since infection is always at equilibrium. It is known that when the number of infected
381 individuals grows exponentially at a constant rate r , the distribution of time since infection
382 equilibrates to an exponential distribution with parameter r (8). Here we assume that the
383 number of infected individuals grows exponentially with rate $r(t)$ and that the time since
384 infection is exponential with parameter $r(t)$ (i.e., the distribution equilibrates instantaneously
385 when $r(t)$ changes). The timing of infections is defined by the probability density $w(\tau)$. Under
386 these assumptions, the effective reproduction number $R(t)$ reflecting transmission and the
387 growth rate $r(t)$ are linked through (8):

$$388 \quad r(t) = \int_0^{\infty} \underbrace{r(t) e^{-r(t)\tau}}_{\substack{\text{stable age} \\ \text{structure}}} \underbrace{w(\tau) R(t)}_{\substack{\text{new infections} \\ \text{from individuals} \\ \text{of age } \tau}} d\tau. \quad (1a)$$

389 The growth rate is the integral over all possible times since infection of the probability that an
390 individual has this age (the exponential distribution), times the number of new infections
391 produced by an individual this age, giving the relation (1a). This equation simplifies to:

$$392 \quad 1 = R(t) \int_0^{\infty} e^{-r(t)\tau} w(\tau) d\tau. \quad (1b)$$

393 For a gamma-distributed generation time (with shape and scale parameters α and β), this
394 integral has an explicit solution:

$$395 \quad R(t) = (1 + \beta r(t))^\alpha. \quad (2)$$

396 Conversely, the growth rate is:

$$397 \quad r(t) = (R(t)^{\frac{1}{\alpha}} - 1) / \beta. \quad (3)$$

398 The epidemic grows when $R(t) > 1$ and declines when $R(t) < 1$. Reparameterising in terms
399 of the mean and standard deviation of the gamma distribution, $\mu = \alpha \beta$ and $\sigma = \sqrt{\alpha} \beta$, yields:

400
$$r(t) = (R(t)^{\sigma^2/\mu^2} - 1)(\mu/\sigma^2). \quad (4)$$

401 Relationship between growth rates of historical strains and emerging variant across
402 epidemiological conditions

403 This equation can separately describe the growth of historical strains and variants characterized
404 by their own parameters: $R_H(t)$, μ_H and σ_H for historical strains, $R_E(t)$, μ_E and σ_E for the
405 emerging variant. We may recast the variant parameters in terms of how they are altered
406 compared to historical strains:

407
$$R_E(t) = R_H(t)(1 + s_1), \quad (5)$$

408
$$\mu_E = \mu_H(1 + s_2),$$

409
$$\sigma_E = \sigma_H(1 + s_3).$$

410 We assume that changes in behaviour and in interventions cause temporal variability in the
411 transmission, measured by the effective reproduction number of historical strains taken as the
412 reference, $R_H(t)$, and only in this parameter. This assumption is valid for interventions that
413 reduce transmission (social distancing, vaccines) but not for interventions that change the
414 distribution of generation time (contact tracing, case isolation). Temporal variability in $R_H(t)$
415 will affect both $r_H(t)$ and $r_E(t)$ through the relationship (4):

416
$$r_H(t) = \left(R_H(t)^{\frac{\sigma_H^2}{\mu_H^2}} - 1 \right) (\mu_H/\sigma_H^2) \quad (6)$$

417
$$r_E(t) = \left(R_E(t)^{\frac{\sigma_E^2}{\mu_E^2}} - 1 \right) (\mu_E/\sigma_E^2) = \left(R_H(t)^{\frac{\sigma_E^2}{\mu_E^2}} (1 + s_1)^{\frac{\sigma_E^2}{\mu_E^2}} - 1 \right) (\mu_E/\sigma_E^2)$$

418 The temporal variation in $R_H(t)$ thus defines a parametric relationship between $r_H(R_H(t))$ and
419 $r_E(R_H(t))$ that can be used to infer s_1 , s_2 and s_3 . The variation of the selection coefficient with
420 $R_H(t)$ is simply given by $r_E(t) - r_H(t)$.

421 Approximation of the parametric relationship

422 To gain further intuition on the parametric relationship between $r_H(R_H(t))$ and $r_E(R_H(t))$ as
423 $R_H(t)$ varies, we compute the tangent of the curve at the value $R_H(t) = 1$ (where r_H is 0). The
424 parameters of this tangent will of course be most informative when values of $R_H(t)$ are not too
425 far from 1. The intercept is:

426
$$\text{intercept} = r_E(1) = \left((1 + s_1) \frac{\sigma_E^2}{\mu_E^2} - 1 \right) (\mu_E / \sigma_E^2) \quad (7)$$

427 Where μ_E and σ_E^2 can be reparameterised with equation (5). This intercept is approximately
428 s_1/μ_H for a variant of small effect (s_1 , s_2 and s_3 are all small). The equation for the slope of
429 the tangent is complicated, but again assuming small-effect variant it can be approximated as:

430
$$\text{slope} \approx 1 + s_1 \text{cv}_H^2 - s_2 \quad (8)$$

431 with the square coefficient of variation of the generation time distribution, $\text{cv}_H^2 = \sigma_H^2/\mu_H^2$. Here
432 it is assumed to be equal to $4^2/6.5^2 = 0.38$. Thus, the slope of the (r_H, r_E) relationship is close
433 to 1, increased by the transmissibility advantage (weighted by cv_H^2), decreased by the change
434 in mean generation time, and unaffected to the first order by the difference in standard deviation
435 s_3 . The selection coefficient is $r_E - r_H$, the vertical distance between the (r_H, r_E) relationship
436 and the bisector.

437 Likelihood:

438 We now formulate the likelihood for the estimated growth rates across time and across regions,
439 denoted by \hat{r}_H and \hat{r}_E . We derive an approximation for the distribution of \hat{r}_H and \hat{r}_E as a function
440 of their true values r_H and r_E and the error variances, under the assumption that these errors are
441 normally distributed and small. The historical strains and emerging variant growth rates are
442 estimated from daily cases and variant frequency time series, by decomposing the cases into
443 historical and emerging variant cases. We will formalise below how the estimated growth rates
444 are affected by the error on variant frequency which depends on $1/N$, where N is sample size,
445 and on the error on cases number.

446 Between two consecutive days, denoted for simplicity days 0 and 1, the observed variables are
447 the total number of cases denoted \hat{I}_0 and \hat{I}_1 and the frequency of variant \hat{p}_0 and \hat{p}_1 . The time is
448 now noted as an index for clarity. The observed total number of cases is:

449
$$\hat{I}_0 = I_0(1 + \epsilon_{I,0}) \quad (9)$$

450
$$\hat{I}_1 = I_1(1 + \epsilon_{I,1})$$

451 We assume that the number of cases is Poisson distributed. When the number of cases is large,
452 the error denoted $\epsilon_{I,0}$ (for day 0) is approximately normally distributed with mean 0 and
453 variance $1/I_0$ (and analogously for day 1). If the number of cases is distributed as a negative
454 binomial (over-dispersed compared to the Poisson), under some conditions the normal

455 approximation may still be accurate and the variance of $\epsilon_{I,0}$ will be $1/[I_0(1-\pi)]$ where π is
456 the success probability of the negative binomial. In other words, the cases number can be
457 reduced to a smaller effective cases number to account for such overdispersion.

458 The observed logit-frequency of the variant is:

$$459 \quad \widehat{lp}_0 = lp_0 + \epsilon_{lp,0} \quad (10)$$

$$460 \quad \widehat{lp}_1 = lp_1 + \epsilon_{lp,1}$$

461 where lp is a shorthand for the logit of the frequency of the variant. In the data, the frequency
462 of the variant was estimated by running a specific PCR on a fraction on all cases and is given
463 by a binomial frequency distribution. If the sample size is large, the error on the logit frequency
464 $\epsilon_{lp,0}$ is approximately normally distributed within mean 0 and variance $1/(N_0 p_0(1-p_0))$
465 where N_0 is the sample size at day 0 (and similarly for day 1, variance $1/(N_1 p_1(1-p_1))$). Here
466 again, it is possible to account for overdispersion compared to the binomial distribution, by
467 reducing the sample size to a smaller effective number.

468 The observed growth rates are linked with the observed variables through the relations:

$$469 \quad \hat{r}_{WT,1} = \log [\hat{I}_{WT,1}/\hat{I}_{WT,0}] = \log [\hat{I}_1(1-\hat{p}_1) / (\hat{I}_0(1-\widehat{p}_0))] \quad (11)$$

$$470 \quad \hat{r}_{V,1} = \log [\hat{I}_{V,1}/\hat{I}_{V,0}] = \log [\hat{I}_1 \hat{p}_1 / (\hat{I}_0 \widehat{p}_0)]$$

471 Small error approximation

472 Replacing the observed number of cases and frequencies with the expressions above, and
473 approximating with a first order Taylor series in the error terms, yields:

$$474 \quad \hat{r}_{H,1} = r_{H,1} + \underbrace{\frac{\epsilon_{I,1} - \epsilon_{I,0}}{\text{error on case incidence}}}_{\text{error on case incidence}} + \underbrace{\frac{p_0 \epsilon_{lp,0} - p_1 \epsilon_{lp,1}}{\text{error on frequency}}}_{\text{error on frequency}} \quad (12)$$

$$475 \quad \hat{r}_{E,1} = r_{E,1} + \epsilon_{I,1} - \epsilon_{I,0} - (1-p_0) \epsilon_{lp,0} + (1-p_1) \epsilon_{lp,1}$$

476 The first two error terms are common to both growth rates and simply express the fact that both
477 growth rates will be inflated if the number of cases is by chance larger at time 1 than at time 0
478 ($\epsilon_{I,1} > \epsilon_{I,0}$). The two last terms express the fact that estimated growth rates will be modified
479 by the error on the estimation of the frequency. For example, the growth rate of the historical
480 strain will be inflated if by chance the error term on frequency at day 0 is greater than that at
481 day 1 ($p_1 \epsilon_{lp,1} < p_0 \epsilon_{lp,0}$). These terms are modulated by the true frequencies p_0 and p_1 .

482 Under the assumption that the errors on the logit frequencies and number of cases are
483 independent and that they are also independent between day 0 and 1, the distribution of
484 $(\hat{r}_{H,1}, \hat{r}_{E,1})$ is bivariate normal. The mean vector is:

$$485 \quad (r_{H,1}, r_{E,1}).$$

486 The variances (diagonal of the variance-covariance matrix) are:

$$487 \quad V[\hat{r}_{H,1}] = V[\epsilon_{I,1}] + V[\epsilon_{I,0}] + p_0^2 V[\epsilon_{lp,0}] + p_1^2 V[\epsilon_{lp,1}]$$

$$488 \quad = 1/I_1 + 1/I_0 + p_0/(N_0(1-p_0)) + p_1/(N_1(1-p_1))$$

$$489 \quad V[\hat{r}_{E,1}] = 1/I_1 + 1/I_0 + (1-p_0)/(N_0 p_0) + (1-p_1)/(N_1 p_1).$$

490 The covariances are:

$$491 \quad \text{cov}[\hat{r}_{H,1}, \hat{r}_{E,1}] = 1/I_1 + 1/I_0 - 1/N_0 - 1/N_1.$$

492 The covariance between the estimated growth rates of historical and emerging strains is
493 expected to be negative, because only a fraction of cases are assayed for the presence of the
494 variant ($N_0 < I_0$). Indeed, the first positive term ($1/I_1 + 1/I_0$) expresses the fact that positive
495 covariance will be created by error in cases number (for example, larger cases number will
496 translate into higher growth rate of both historical strains and variant). The second negative
497 term expresses the fact that the error in estimation of variant frequency will impact $\hat{r}_{H,1}$ and $\hat{r}_{E,1}$
498 in opposite ways. This second negative effect will be dominant.

499 Definition of the likelihood

500 Likelihood for temporal dynamics

501 We now formulate more generally the likelihood of observed growth rates at all days t , $\hat{r}_{H,t}, \hat{r}_{E,t}$
502 with $t \in [1, t_{max}]$. Across consecutive timepoints, successive estimates of $\hat{r}_{H,1}, \hat{r}_{E,1}$ will also
503 be correlated because they share the same error terms. These cross-time covariances will be:

$$504 \quad \text{cov}[\hat{r}_{H,t}, \hat{r}_{H,t+1}] = \text{cov}[\epsilon_{I,t} - p_t \epsilon_{lp,t}, -\epsilon_{I,t} + p_t \epsilon_{lp,t}]$$

$$505 \quad = -V[\epsilon_{I,t}] - p_t^2 V[\epsilon_{lp,t}]$$

$$506 \quad = -1/I_t - p_t/(N_t(1-p_t))$$

$$507 \quad \text{cov}[\hat{r}_{E,t}, \hat{r}_{E,t+1}] = -1/I_t - (1-p_t)/(N_t p_t)$$

$$508 \quad \text{cov}[\hat{r}_{E,t}, \hat{r}_{H,t+1}] = -1/I_t + 1/N_t$$

509
$$\text{cov}[\hat{r}_{H,t}, \hat{r}_{E,t+1}] = -1/I_t + 1/N_t$$

510 Finally, the likelihood for the estimated growth rates of historical strain and mutant within a
511 region at all days is given by the density of the multivariate normal distribution:

512
$$P(\hat{r}_{H,1}, \hat{r}_{E,1}, \dots, \hat{r}_{H,t_{max}}, \hat{r}_{E,t_{max}} \mid R_{H,1}, \dots, R_{H,t_{max}}, s_1, s_2, s_3)$$

513
$$= f_{\mathbf{m}, \Sigma}(\hat{r}_{H,1}, \hat{r}_{E,1}, \dots, \hat{r}_{H,t_{max}}, \hat{r}_{E,t_{max}}) \quad (13)$$

514 where $f_{\mathbf{m}, \Sigma}$ is the density of the multivariate normal distribution. The mean vector \mathbf{m} is
515 composed of the true growth rates, which depend in turn on the temporal series of true
516 transmissibility of historical strains $R_{H,1}, \dots, R_{H,t_{max}}$, the temporal series of true transmissibility
517 of the variant $R_{H,1}(1 + s_1), \dots, R_{H,t_{max}}(1 + s_1)$, and the distribution of the generation time of
518 the variant characterized by s_2, s_3 . The distribution of the generation time of historical strains
519 is assumed to be known. The covariance matrix Σ is block-diagonal with non-zero covariances
520 between mutant and historical strains at the same time and at consecutive time-points, as given
521 above. The true number of cases I_t , sample size N_t , and the true variant frequencies p_t ,
522 intervene in the expressions for the variances and covariances. In practice we approximate the
523 true number of cases and variant frequencies by their estimations, \hat{I}_t and \hat{p}_t .

524 Likelihood for spatial variation

525 The likelihood of a series of growth rates $\hat{r}_{H,i}, \hat{r}_{E,i}$ collected in different regions or countries
526 indexed by i is different from that for a temporal series of $\hat{r}_{H,t}, \hat{r}_{E,t}$, because there are no
527 correlations between growth rates measured in different countries (in contrast to temporal
528 correlations). For such data representing spatial variation in growth rates, the mean vector is
529 composed of the true growth rates, which depend on the transmissibilities in different countries
530 $R_{H,i}$. The covariance matrix has diagonal given by the variances:

531
$$V[\hat{r}_{H,i}] = 1/I_{1,i} + 1/I_{0,i} + p_{0,i}/(N_{0,i}(1-p_{0,i})) + p_{1,i}/(N_{1,i}(1-p_{1,i}))$$

532
$$V[\hat{r}_{E,i}] = 1/I_{1,i} + 1/I_{0,i} + (1 - p_{0,i})/(N_{0,i}p_{0,i}) + (1 - p_{1,i})/(N_{1,i}p_{1,i}).$$

533 Where 0 and 1 are the consecutive timepoints at which the growth rates are measured, and the
534 index i denotes the country. Furthermore, the covariances between growth rates of historical
535 strains and emerging variants are:

536
$$\text{cov}[\hat{r}_{H,i}, \hat{r}_{E,i}] = 1/I_{1,i} + 1/I_{0,i} - 1/N_{0,i} - 1/N_{1,i}.$$

537 All other covariances (between quantities measured in different countries) are 0.

538 Simulation study

539 Our approach relies on several approximations. First, we assume that the age-of-infection
 540 structure of the population is always at equilibrium with the current growth rate $r(t)$ even
 541 though transmission $R(t)$ changes over time. Second, we assume that errors around cases
 542 number and frequencies are small and normally distributed. We conducted a simulation study
 543 to test our ability to infer the parameters of the variant infectivity profile in spite of these
 544 approximations.

545 Description of the simulation model

546 The simulation model is as in a previous study (24) and includes time-varying transmission,
 547 arbitrary infectivity profiles, the build-up of population immunity, and detection and isolation
 548 of cases. To model transmission dynamics, we use a discretized version of the renewal equation
 549 (see also (25)) extended to two strains, historical strains and the variant. We follow the
 550 dynamics of the number of individuals infected at day t who were infected τ days ago, and have
 551 not yet been detected and isolated, called $I_H(t, \tau)$ and $I_E(t, \tau)$. The transmission dynamics are
 552 given by the system of recurrence equations:

$$553 \quad I_H(t + 1, 0) = R_{0,H}(t) \underbrace{(1 - I_t^{tot}/S_0)}_{\substack{\text{population} \\ \text{immunity}}} \underbrace{\sum_{\tau=0}^{\infty} w_H(\tau) I_H(t, \tau)}_{\substack{\text{infectivity} \\ \text{profile}}} \quad (14)$$

$$554 \quad I_E(t + 1, 0) = R_{0,E}(t) (1 - I_t^{tot}/S_0) \sum_{\tau=0}^{\infty} w_E(\tau) I_E(t, \tau)$$

$$555 \quad I_H(t + 1, \tau) = I_H(t, \tau - 1) \underbrace{(1 - c y(\tau - 1))}_{\substack{\text{case detection} \\ \text{and isolation}}} \quad \forall \tau \geq 1$$

$$556 \quad I_E(t + 1, \tau) = I_E(t, \tau - 1)(1 - c y(\tau - 1)) \quad \forall \tau \geq 1$$

557 The first two equations are analogous and represent transmission to new susceptible individuals
 558 giving rise to infected individuals with time since infection 0. The parameter $R_{0,H}(t)$ reflects
 559 transmission of historical strains, and is the basic reproduction number (in the absence of
 560 interventions, and when the population is fully susceptible, i.e. $I_t^{tot} = 0$). The factor $w_H(\tau)$ is
 561 the fraction of transmission that occurs at time since infection τ , where $\sum_{\tau=0}^{\infty} w_H(\tau) = 1$. Thus
 562 $w_H(\tau)$ represents the distribution of the generation time of the virus. In practice, we use a
 563 discretized version of the gamma distribution. The infectivity profile of the virus is the product
 564 of transmissibility and the generation time distribution $R_{0,H}(t) w_H(\tau)$. Transmission is reduced
 565 by a factor $1 - I_t^{tot}/S_0$ by population immunity, where S_0 is the initial number of susceptible

566 individuals in the region. Population immunity is assumed to be the same for both variants
567 (perfect cross-protection). The variable $I_t^{tot} = \sum_{i=1}^t (I_H(i, 0) + I_E(i, 0))$ is the total number of
568 individuals already infected and assumed to be fully immune at time t . The instantaneous
569 reproduction number that accounts for population immunity but not for case isolation is
570 $R_H(t) = R_{0,H}(t) (1 - I_t^{tot} / S_0)$.

571 The third and fourth equations are analogous and represent the dynamics of individuals infected
572 in the past. Individuals infected $\tau - 1$ days ago now have time since infection τ , provided they
573 were not detected and isolated. An infected individual is detected with probability c , and the
574 probability that an individual is detected at age τ (when it is detected) is given by $y(\tau)$, with
575 $\sum_{\tau=1}^{\infty} y(\tau) = 1$. An individual who is detected is removed from the pool of individuals that
576 contribute to further transmission of the disease. The total number of cases detected at day t is
577 thus:

$$578 \quad C_H(t) = c \sum_{\tau=0}^{\infty} y(\tau) I_H(t, \tau) \quad (15)$$

$$579 \quad C_E(t) = c \sum_{\tau=0}^{\infty} y(\tau) I_E(t, \tau)$$

580 And the number of detected individuals who were infected τ days ago changes as:

$$581 \quad C(t + 1, 0) = 0 \quad (\text{when } \tau = 0) \quad (16)$$

$$582 \quad C(t + 1, \tau) = C(t, \tau - 1) + c I(t, \tau - 1) y(\tau - 1) \quad \forall \tau \geq 1$$

583 **Parameterisation of the simulation model**

584 We simulate the epidemiological dynamics of historical strains and variant virus. We assume
585 that historical strains initially grow slowly, while the emerging variant initially increases in
586 incidence faster thanks to its transmissibility advantage. Control measures are progressively
587 strengthened, leading to control of historical strains and then the variant. Over the period
588 considered, the variant initially increases in frequency.

589 We ran the simulation for 80 days. We first ran a simulation where we assumed the basic
590 reproduction number $R_{0,H}(t)$ changed as a Brownian motion with mean 1.5 and autocorrelation
591 0.05, and selected a trajectory such that the mean $R_{0,t}$ over the 20 first days exceeded 1.1 and
592 the mean over the 20 last days was below 0.9 (Figure 2). For systematic simulations designed
593 to test the inference algorithm, we chose three scenarios for the temporal variation in $R_{0,H}(t)$:
594 linear decline from 1.5 to 0.5, from 1.3 to 0.7, and from 1.1 to 0.9. We assumed about 9M
595 individuals are initially susceptible (corresponding to a large European region), and an initial

596 number of detected cases of 4000 historical strains infections per day and 80 variant infections
597 per day. We assumed 50% of all infection are detected (probability of detection $c = 0.5$). The
598 time to detection is the sum of time from infection to symptom onset (distributed as log-normal
599 with parameters 1.518, 0.472 (26)), and the time from symptom to detection (distributed as
600 gamma with parameters shape 0.69, rate 0.31 (24,26)). We assumed the generation time of
601 historical strains was gamma distributed with mean 6.5 days and standard deviation 4 days (2).

602 **Inference**

603 For inference, we tested combinations of the s_1 , s_2 parameters describing how the variant
604 differs from the historical strains in its transmissibility and mean generation time. In the terms
605 of the simulation model parameters, $R_{0,E}(t) = R_{0,H}(t)(1 + s_1)$. The parameter s_2 affects the
606 parameters of the gamma distribution describing $w_E(\tau)$, while $w_H(\tau)$ is gamma-distributed
607 with mean 6.5 days and standard deviation (sd) 4 days. We assumed the variant had the same
608 standard deviation of generation time, $s_3 = 0$. Indeed, variants affecting the sd of generation
609 time distribution have a very small selection coefficient which makes inference of this
610 parameter difficult. This is seen by initial exploration of the relationship between growth rates
611 of historical strains and variant, \hat{r}_H and \hat{r}_E (Supplementary Figure 1).

612 We systematically tested our ability to infer the s_1 and s_2 parameters. We ran the simulation
613 model for all combinations of s_1 from 0 to 0.5 in steps of 0.1 (transmissibility advantage
614 increased from +0% to +100%), and of s_2 from -0.4 to 0.4 in steps of 0.2. We inferred the
615 parameters s_1 and s_2 by maximum likelihood using the expression for the likelihood in
616 equation (13).

617 *Heuristic for the simulation study*

618 In principle we need to infer jointly the parameters of interest $\{s_1, s_2\}$, together with the other
619 unknown parameters $\{R_{H,1}, \dots, R_{H,t_{max}}\}$, which can be many. We used a simplified heuristic
620 whereby we first set the parameters $\{R_{H,1}, \dots, R_{H,t_{max}}\}$ to plausible values given $\{s_1, s_2\}$, then
621 infer the maximum likelihood parameters $\{s_1, s_2\}$ given $\{R_{H,1}, \dots, R_{H,t_{max}}\}$, and so on. We
622 inferred maximum likelihood parameters $\{s_1, s_2\}$ using the “BFGS” (Broyden, Fletcher,
623 Goldfarb and Shanno) method implemented in the optim function in the software R (27). In the
624 simulation study, we iterate this procedure five times with five different starting points for
625 $\{s_1, s_2\}$ and select the final maximum likelihood parameter set $\{s_1, s_2, R_{H,1}, \dots, R_{H,t_{max}}\}$.

626 To set $\{R_{H,1}, \dots, R_{H,t_{max}}\}$ to plausible values, we used the measured growth rates with a
627 simplified likelihood function. The simplified likelihood does not consider the full covariance
628 structure of the multivariate normal distribution but instead only use the variances of the
629 distribution $V[\hat{r}_{H,i}]$ and $V[\hat{r}_{E,i}]$ expressed above. Given $\{s_1, s_2\}$, we set the historical strains
630 transmissibilities to:

$$631 \quad R_{H,i} = \left[\frac{1}{V[\hat{r}_{H,i}]} \left(1 + \frac{\sigma^2}{\mu} \hat{r}_{H,i}\right)^{\mu^2/\sigma^2} + \frac{1}{V[\hat{r}_{E,i}]} \frac{1}{1+s_1} \left(1 + \frac{\sigma^2}{\mu(1+s_2)} \hat{r}_{E,i}\right)^{\mu^2(1+s_2)^2/\sigma^2} \right] \left(\frac{1}{V[\hat{r}_{H,i}]} + \frac{1}{V[\hat{r}_{E,i}]} \right)^{-1} \quad (17)$$

632 This equation stems from equation (2) linking growth rates with effective reproduction number.
633 It is reparameterised in terms of μ and σ , the mean and standard deviation of the distribution
634 of the generation time of the historical strains. It is a weighted sum of the effective reproduction
635 number as estimated from the historical strains growth rate $\hat{r}_{H,i}$, and the effective reproduction
636 number as estimated from the variant growth rate $\hat{r}_{E,i}$. For the latter the mean generation time
637 is altered by $(1 + s_2)$, and the transmissibility is altered by $(1 + s_1)$. The weights are the
638 inverse variance of each of the estimated growth rates, $1/V[\hat{r}_{H,i}]$ and $1/V[\hat{r}_{E,i}]$.

639 The estimated growth rate of the historical strains and variants at time i are given by equation
640 (11) applied to each time-point:

$$641 \quad \hat{r}_{H,i} = \log[\hat{I}_{i+1}(1 - \hat{p}_{i+1}) / (\hat{I}_i(1 - \hat{p}_i))] \quad (18)$$

$$642 \quad \hat{r}_{E,i} = \log[(\hat{I}_{i+1} \hat{p}_{i+1}) / (\hat{I}_i \hat{p}_i)]$$

643 We systematically verified in the simulations that this heuristic converged to a set of $R_{H,i}$ close
644 to the true effective reproduction number.

645 *Full inference for analysis of English and European data*

646 We ran inference on three datasets, two based on temporal variation in growth rates in England,
647 and the third based on spatial variation across European countries:

648 (1) Data on the growth of the Alpha variant in England from 08/09/2020 to 16/03/2021. The
649 frequency of the Alpha variant is estimated from “S-gene target failures” which reflect the
650 deletion 69-70 in the gene S typical of Alpha.

651 (2) Data on the growth of the Delta variant in England from 23/03/2021 to 15/06/2021. The
652 frequency of the Delta variant is again estimated from “S-gene target failures”, where this time
653 the “historical strains” is the Alpha variant and the Delta variant which does not have the del69-
654 70 in gene S emerges.

655 (3) TESSy data from the European Centre for Disease Prevention and Control (28), on the
656 growth of the Delta variant based on viral isolates sequenced in eleven European countries:
657 Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Norway,
658 Sweden. We selected countries with sufficient data (based on visual inspection of the frequency
659 trajectory of Delta), and used for each country the growth rates between the two weeks when
660 the frequency of the Delta variant passed 50%.

661 As these datasets present a limited number of weeks or countries, it was possible to directly
662 infer jointly the complete parameter set, $\{s_1, s_2, R_{H,1}, \dots, R_{H,t_{max}}\}$ for temporal datasets,
663 $\{s_1, s_2, R_{H,1}, \dots, R_{H,n_c}\}$ for the spatial dataset where $n_c = 11$ is the number of countries.
664 Furthermore, we ran optimisations for several effective number of cases and sample sizes, to
665 select the best amount of overdispersion (Supplementary Figure 4). Each optimisation is
666 conducted with 30 iterations of the BFGS algorithm with 30 random initial parameter values,
667 and selecting the final best optimisation. The 95% confidence intervals on the parameters were
668 computed assuming multivariate normality of the likelihood function, and estimating the
669 Hessian matrix of this multivariate normal at the optimum.

670

671 **Acknowledgements:** FB was funded by a Momentum grant from CNRS. We thank Public
672 Health England and The European Surveillance System (TESSy) of the European Centre for
673 Disease Prevention and Control for sharing data on variant frequency.

674 **Competing interests:** none.

675


676

677 References

- 678 1. Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, et al. Evaluating the
679 Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
680 *Cell*. 2021 Jan 7;184(1):64-75.e11.
- 681 2. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
682 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*. 2021 Mar 25;1–17.
- 683 3. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.
684 Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
685 *Science* [Internet]. 2021 Apr 9 [cited 2021 Apr 16];372(6538). Available from:
686 <https://science.sciencemag.org/content/372/6538/eabg3055>
- 687 4. Borges V, Sousa C, Menezes L, Gonçalves AM, Picão M, Almeida JP, et al. Tracking
688 SARS-CoV-2 VOC 202012/01 (lineage B. 1.1. 7) dissemination in Portugal: insights
689 from nationwide RT-PCR Spike gene drop out data. *Viol Org*. 2021;
- 690 5. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM,
691 et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.
692 *Cell* [Internet]. 2021 Mar 30 [cited 2021 Apr 16]; Available from:
693 <https://www.sciencedirect.com/science/article/pii/S0092867421003834>
- 694 6. Gaymard A, Bosetti P, Feri A, Destras G, Enouf V, Andronico A, et al. Early
695 assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1
696 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021.
697 *Eurosurveillance*. 2021 Mar 4;26(9):2100133.
- 698 7. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
699 Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at
700 June 2021. *Eurosurveillance*. 2021 Jun 17;26(24):2100509.
- 701 8. Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth
702 rates and reproductive numbers. *Proc R Soc B Biol Sci*. 2007 Feb 22;274(1609):599–
703 604.
- 704 9. Park SW, Bolker BM, Funk S, Metcalf CJE, Weitz JS, Grenfell BT, et al. Roles of
705 generation-interval distributions in shaping relative epidemic strength, speed, and
706 control of new SARS-CoV-2 variants. *medRxiv*. 2021 May 5;2021.05.03.21256545.
- 707 10. Public Health England. SARS-CoV-2 variants of concern and variants under
708 investigation Technical Briefing 9 [Internet]. Public Health Engalnd; [cited 2021 Jun
709 21]. Report No.: 9. Available from:
710 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment
711 _data/file/979818/Variants_of_Concern_VOC_Technical_Briefing_9_England.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/979818/Variants_of_Concern_VOC_Technical_Briefing_9_England.pdf)
- 712 11. Public Health England. SARS-CoV-2 variants of concern and variants under
713 investigation Technical Briefing 17 [Internet]. Public Health Engalnd; [cited 2021 Jun
714 21]. Report No.: 17. Available from:

- 715 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001354/Variants_of_Concern_VOC_Technical_Briefing_17.pdf)
716 [_data/file/1001354/Variants_of_Concern_VOC_Technical_Briefing_17.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001354/Variants_of_Concern_VOC_Technical_Briefing_17.pdf)
- 717 12. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral dynamics
718 of SARS-CoV-2 variants in vaccinated and unvaccinated individuals [Internet]. 2021
719 Aug [cited 2021 Sep 25] p. 2021.02.16.21251535. Available from:
720 <https://www.medrxiv.org/content/10.1101/2021.02.16.21251535v3>
- 721 13. Cosentino G, Bernard M, Ambroise J, Giannoli J-M, Guedj J, Débarre F, et al. SARS-
722 CoV-2 viral dynamics in infections with variants of concern in the French community
723 [Internet]. 2021 [cited 2021 May 18]. Available from: [https://hal.sorbonne-](https://hal.sorbonne-universite.fr/hal-03217231)
724 [universite.fr/hal-03217231](https://hal.sorbonne-universite.fr/hal-03217231)
- 725 14. Elie B, Lecorche E, Sofonea MT, Trombert-Paolantoni S, Foulongne V, Guedj J, et al.
726 Inferring SARS-CoV-2 variant within-host kinetics [Internet]. 2021 May [cited 2021
727 Sep 25] p. 2021.05.26.21257835. Available from:
728 <https://www.medrxiv.org/content/10.1101/2021.05.26.21257835v1>
- 729 15. Zhang M, Xiao J, Deng A, Zhang Y, Zhuang Y, Hu T, et al. Transmission Dynamics of
730 an Outbreak of the COVID-19 Delta Variant B.1.617.2 — Guangdong Province, China,
731 May–June 2021. *China CDC Wkly.* 2021 Jul 2;3(27):584–6.
- 732 16. Pung R, Mak TM, Group CC-19 working, Kucharski AJ, Lee VJ. Serial intervals
733 observed in SARS-CoV-2 B.1.617.2 variant cases. *medRxiv.* 2021 Jun
734 4;2021.06.04.21258205.
- 735 17. Ryu S, Kim D, Lim J-S, Ali ST, Cowling BJ. Serial interval and transmission dynamics
736 during the SARS-CoV-2 Delta variant predominance in South Korea [Internet]. 2021
737 Oct [cited 2021 Oct 27] p. 2021.08.18.21262166. Available from:
738 <https://www.medrxiv.org/content/10.1101/2021.08.18.21262166v2>
- 739 18. Alizon S, Haim-Boukobza S, Foulongne V, Verdurme L, Trombert-Paolantoni S,
740 Lecorche E, et al. Rapid spread of the SARS-CoV-2 δ variant in the area of Paris
741 (France) in June 2021. *medRxiv.* 2021 Jun 20;2021.06.16.21259052.
- 742 19. Blanquart F, Abad C, Ambroise J, Bernard M, Cosentino G, Giannoli J-M, et al. Spread
743 of the Delta variant, vaccine effectiveness against PCR-detected infections and within-
744 host viral load dynamics in the community in France [Internet]. 2021 [cited 2021 Jul
745 21]. Available from: <https://hal.archives-ouvertes.fr/hal-03289443>
- 746 20. Roquebert B, Trombert-Paolantoni S, Haim-Boukobza S, Lecorche E, Verdurme L,
747 Foulongne V, et al. The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the
748 B.1.1.7 lineage (VOC α) in some French regions in April 2021. *Eurosurveillance.* 2021
749 Jun 10;26(23):2100447.
- 750 21. Kraemer MUG, Pybus OG, Fraser C, Cauchemez S, Rambaut A, Cowling BJ.
751 Monitoring key epidemiological parameters of SARS-CoV-2 transmission. *Nat Med.*
752 2021 Nov 8;1–2.
- 753 22. Roquebert B, Haim-Boukobza S, Trombert-Paolantoni S, Lecorche E, Verdurme L,
754 Foulongne V, et al. SARS-CoV-2 variants of concern are associated with lower RT-

- 755 PCR amplification cycles between January and March 2021 in France. medRxiv. 2021
756 Mar 22;2021.03.19.21253971.
- 757 23. Public Health England. SARS-CoV-2 variants of concern and variants under
758 investigation in England. Technical Briefing 16 [Internet]. 2021 Jun [cited 2021 Jun 28].
759 Available from:
760 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/994997/Variants_of_Concern_VOC_Technical_Briefing_16.pdf)
761 [_data/file/994997/Variants_of_Concern_VOC_Technical_Briefing_16.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/994997/Variants_of_Concern_VOC_Technical_Briefing_16.pdf)
- 762 24. Belloir A, Blanquart F. Estimating the global reduction in transmission and rise in
763 detection capacity of the novel coronavirus SARS-CoV-2 in early 2020. *Epidemics*.
764 2021 Jun 1;35:100445.
- 765 25. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating
766 the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020
767 Jun 8;1–8.
- 768 26. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation
769 Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed
770 Cases: Estimation and Application. *Ann Intern Med*. 2020 Mar 10;172(9):577–82.
- 771 27. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna,
772 Austria: R Foundation for Statistical Computing; 2018.
- 773 28. Data on SARS-CoV-2 variants in the EU/EEA [Internet]. European Centre for Disease
774 Prevention and Control. 2021 [cited 2021 Sep 24]. Available from:
775 <https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covid-19-eueea>
- 776
- 777




778

779 **Supplementary Figure 1:** The relationship between estimated growth rate of the variant and historical strains
780 across time in the simulation study, in the scenario of progressive decline of $R_{0,H}(t)$ from 1.5 to 0.5. The three
781 panels are three daily sample sizes to assess variant frequency (30000, 10000, 3000). This is shown for variants
782 with no transmissibility advantage $s_1 = 0$, and four scenarios of infectivity profiles: shorter mean generation time
783 ($s_2 = -0.4, s_3 = 0$), longer mean generation time ($s_2 = +0.4, s_3 = 0$), larger sd ($s_2 = 0, s_3 = +0.4$) and smaller
784 sd ($s_2 = 0, s_3 = -0.4$). Points are the estimated growth rates with error, the curves show local polynomial
785 regression (loess). The selection coefficient is the vertical distance to the bisector. A variant with a shorter mean
786 generation time presents a steeper relationship between the two growth rates (light blue curve), meaning that the
787 selection coefficient is maximal when transmission is large (fast growing epidemic) (Figure 1C, D). On the
788 contrary, a variant with a longer generation time presents a flatter relationship (dark blue curve), with selection
789 coefficient being maximal when transmission is small. This distinction blurs when the number of cases sampled
790 to assess variant frequency decreases. Variants changing the variance of the distribution (green curves) appear
791 almost neutral, with curves close to the bisector.

792

793

794




795

796 **Supplementary Figure 2:** The daily basic reproduction number of the historical strains and variant ($R_{0,H}(t)$ and
797 $R_{0,E}(t)$, identical thick lines), together with the effective reproduction number inferred from daily case and
798 frequency data (thin lines), in the example simulation shown on Figure 2B for an emerging variant with +10%
799 effective reproduction number and same distribution of generation time. These realized effective reproduction
800 number present a trend similar to the true basic reproduction number inputted to the simulation with three
801 differences. First, the realized effective reproduction number are shifted in time compared to $R_{0,H}(t)$ because of
802 the time shift between infections and case detection. Second, the realized effective reproduction number is lower
803 than the true $R_{0,H}(t)$ because of population immunity and case detection and isolation. Third, error in cases
804 numbers and in variant frequency cause error in the inferred effective reproduction number.

805


806



807

808 **Supplementary Figure 3:** The effective reproduction number of historical strains $R_H(t)$ estimated on the English
809 data, for the period when the Alpha variant emerged and replaced historical strains, then the period when the Delta
810 variant emerged and replaced the Alpha variant and other strains. The two periods are separated by the dashed
811 vertical line. Black points show the maximum likelihood estimates, red shaded areas the 95% confidence interval.

812



813

814 **Supplementary Figure 4:** Negative log-likelihood of the fully optimised model as a function of overdispersion
815 in number of cases and in emerging variant frequency. Overdispersion is represented by two factors: a factor
816 reducing the number of cases, thus increasing the variance of the error in cases number compared to a Poisson,
817 and a factor reducing the sample size, thus increasing the variance in frequency compared to a binomial. We
818 optimised likelihood for all combinations of the two factors. Top panels, negative likelihood of the optimised
819 model as function of the factor reducing the number of cases. Bottom panels, as a function of the factor reducing
820 the sample size. The best combination of factors is highlighted as an open point. This is shown for the three
821 datasets (left, middle, right columns).

822